On 19 November 2024, Xbrane and Intas announced they have entered an exclusive, global licensing and co-development agreement in relation to Xbrane´s nivolumab biosimilar candidate (referencing BMS’ Opdivo®). The biosimilar will be commercialised through Intas’ subsidiary Accord Healthcare.
Under the agreement, Xbrane will receive an upfront payment of 10 million euros plus milestone payments of 3 million euros and royalties on profits. Intas will finance and oversee the clinical and regulatory development activities and the global commercialisation of the biosimilar.
This announcement is in line with Xbrane’s previously published, updated expectation of finalising this agreement by the end of November 2024. Xbrane says the product will be launched after expiry of relevant patents in the US in December 2028 and Europe in June 2030.
This deal adds to Intas’ portfolio of licensed biologics and biosimilars which includes:
- Meiji and Dong-A St’s Imuldosa® (DMB-3115) and Absimky® (DMB-3115), biosimilars to Janssen’s Stelara® (ustekinumab);
- Henlius’ biopharmaceutical, Hetronifly® (serplulimab); and
- Axantia’s ranibizumab, biosimilar to Genetech’s Lucentis®.